AstraZeneca, Merck secure EU nod for Lynparza to treat germline BRCA-mutated metastatic pancreatic cancer

AstraZeneca and Merck have secured EU approval for Lynparza to treat germline BRCA-mutated metastatic pancreatic cancer. (Credit: AstraZeneca)